Asciminib Represents New Safe and Effective Treatment Option for Heavily Pretreated CML
December 6th 2020A real-world analysis showed the positive safety and efficacy of the investigational tyrosine kinase inhibitor asciminib as treatment of patients with chronic myeloid leukemia without any alternatives in clinical practice.
Immunotherapy Advances Treatment Landscape for Small Cell Lung Cancer
November 7th 2020An important milestone in the treatment landscape of extensive-stage small cell lung cancer has been trials of first-line chemoimmunotherapy. However, a study that requires better understanding of the methods and can be used to determine patients who are likely to experience durable benefits to therapy is currently concentrated.
Survival Improvement Observed with Cemiplimab in Frontline Advanced PD-L1+ NSCLC
September 21st 2020In the phase 3 EMPOWER-Lung 1 trial, patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells, had a significant improvement in overall survival and progression-free survival with cemiplimab-rwlc monotherapy compared with platinum-doublet chemotherapy.
Responses, Favorable Safety Profile Reported for Amivantamab Plus Lazertinib in EGFR+ NSCLC
September 20th 2020Findings from the phase 1 CHRYSALIS study showed that patients with advanced EGFR-mutant non–small cell lung cancer who were treatment naïve or resistant to osimertinib therapy had high response rates when treated with the combination of amivantamab and lazertinib. Results also demonstrated a favorable safety profile for the regimen, according to results reported at the ESMO Virtual Congress 2020.
In High-Risk Early Breast Cancer, Risk of Recurrence Is Reduced With Abemaciclib
September 20th 2020Findings from the phase 3 monarchE trial reported at the ESMO Virtual Congress 2020 showed that the risk of invasive disease with abemaciclib plus endocrine therapy was significantly reduced versus endocrine therapy alone in patients with high-risk early hormone receptor-positive, HER2-negative breast cancer.
Ipatasertib Combination Misses End Points in HR+ HER2- Advanced Breast Cancer
September 19th 2020An improvement in progression-free survival and objective response rate was not observed with the addition of ipatasertib to paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.
Eprenetapopt Plus Azacitidine Yields Promising Responses in High-Risk MDS/AML
June 14th 2020"The data from this ongoing trial of eprenetapopt with azacitidine continue to be very encouraging in these most difficult-to-treat [patients with] TP53-mutant MDS and AML, who not only have at least one TP53 mutation but the majority of whom also have high risk cytogenetic abnormalities,."
Investigation of Tepotinib Shows Durable Benefit in NSCLC With a METex14 Skipping Mutation
May 31st 2020Durable clinical activity was demonstrated with tepotinib, an oral, highly selective MET inhibitor, in patients with locally advanced or metastatic non–small cell lung cancer and a MET exon 14 skipping mutation identified through liquid or tissue biopsy. This data was from the phase 2 VISION trial presented during the at the 2020 Virtual Scientific Meeting and published in the New England Journal of Medicine.
Pembrolizumab Extends PFS in Newly Diagnosed MSI-H/dMMR mCRC
May 28th 2020"Pembrolizumab works in non-randomized studies in this group of patients with advanced disease. This randomized study demonstrates a huge benefit in the first-line [setting] with pembrolizumab and should be the new standard of care."
Bendamustine Plus Rituximab Demonstrates Efficacy as Induction Therapy in MCL
February 26th 2020In an interview with Targeted Oncology at the 2019 ASH Annual Meeting, Diego Villa, MD, MPH, discussed the benefit of bendamustine plus rituximab versus R-CHOP in transplant-eligible and -ineligible patients with mantle cell lymphoma.
Patients With BRAF+ non-V600 Colorectal Cancer May Be Sensitive to Anti-EGFR Therapy
September 21st 2019Certain patients with BRAF non-V600-mutant, RAS-dependent metastatic colorectal cancer may be sensitive to anti-EGFR therapy, according to the results of a a multicenter pooled analysis recently published in Clinical Cancer Research. The analysis suggested that those with RAS<em>-</em>dependent tumors were more likely to respond to anti-EGFR therapy than those with RAS-independent tumors.
Stimulatory Effects Observed With Vaccine in Early-Stage CRC
May 20th 2019Investigators on a first-in-human phase I trial found that antibody and T-cell responses were detected in a vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer.<br />
Small Molecule Demonstrates Activity Against Ibrutinib-Resistant MCL
May 20th 2019Preclinical data suggest that the small molecule IACS-10759, which targets the oxidative phosphorylation and glutaminolysis pathways, may play a critical role in overcoming resistance to ibrutinib in mantle cell lymphoma.
Study Confirms Initial Monitoring Strategy Effective in MCL
April 23rd 2019In a recent retrospective analysis, investigators found that initially observing patients with mantle cell lymphoma based solely on clinical criteria was an effective management strategy that did not compromise patient outcomes.
Childhood Cancer Associated With Increased Risk for Developing Skin Cancers
March 27th 2019According to new data, survivors of childhood cancer who have lived 5 or more years from their primary malignancy may be up to 30 times more likely to develop a skin malignancy compared with the general population.
Early Findings Show Activity With Neoadjuvant Pembrolizumab Regimen in TNBC
March 1st 2019According to preliminary findings from the phase Ib KEYNOTE-173 trial, combining the PD-1 inhibitor pembrolizumab with platinum/taxane chemotherapy led to high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.
Expert Highlights Importance of Genetic Testing in Gynecologic Cancers
February 27th 2019According to Huma Q. Rana, MD, genetic testing provides valuable benefit in the treatment landscape of gynecologic cancers. It can inform physicians of the individual and familial risk for developing a malignancy, alert patients of potential screening and preventative measures, and guide selection of potential targeted therapies.
Finasteride Effective in Preventing Prostate Cancer
February 15th 2019According to the final analysis of the Prostate Cancer Prevention Trial, finasteride, an agent commonly used to treat lower urinary tract problems and baldness in men, was safe and effective in reducing the risk of prostate cancer.
Expert Discusses Abemaciclib Monotherapy in HR+/HER2- Breast Cancer
January 30th 2019In findings from the phase II next MONARCH 1 trial, single-agent abemaciclib continued to be safe and effective for patients with hormone receptor–positive, HER2-negative advanced breast cancer who have progressed on or following endocrine therapy.